|
Video: What is a Stock Split?
|
|
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions with unmet medical needs. Co.'s main platform technologies include: semaphorin 4D (SEMA4D) antibody platform, which is the application of its knowledge of SEMA4D biology to develop its main product candidate pepinemab for the treatment of various indications, including cancer and neuroinflammatory and neurodegenerative diseases; and ActivMAb antibody discovery platform, which is a proprietary human antibody discovery platform based on a method for expressing libraries of human monoclonal antibodies on the surface of mammalian pox viruses. According to our VCNX split history records, Vaccinex has had 2 splits. | |
|
Vaccinex (VCNX) has 2 splits in our VCNX split history database. The first split for VCNX took place on September 26, 2023. This was a 1 for 15 reverse split, meaning for each 15 shares of VCNX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split. VCNX's second split took place on February 20, 2024. This was a 1 for 14 reverse split, meaning for each 14 shares of VCNX owned pre-split, the shareholder now owned 1 share. For example, a 66.6666666666667 share position pre-split, became a 4.76190476190476 share position following the split.
When a company such as Vaccinex conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the VCNX split history from start to finish, an original position size of 1000 shares would have turned into 4.76190476190476 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vaccinex shares, starting with a $10,000 purchase of VCNX, presented on a split-history-adjusted basis factoring in the complete VCNX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/10/2018 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$2,415.00 |
|
End price/share: |
$7.41 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.69% |
|
Average Annual Total Return: |
-64.18% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$30.71 |
|
Years: |
5.64 |
|
|
|
Date |
Ratio |
09/26/2023 | 1 for 15 | 02/20/2024 | 1 for 14 |
|
|